A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 18, 2019

Primary Completion Date

March 16, 2021

Study Completion Date

March 16, 2021

Conditions

Mitochondrial DiseasesMitochondrial Respiratory Chain DeficienciesMELAS SyndromeMitochondrial Myopathies

Interventions

DRUG

KL1333

25 and 100 mg KL1333 encapsulated tablets

DRUG

Placebo Oral Tablet

25 and 100 mg placebo encapsulated tablets

Trial Locations (2)

Covance Leeds, Leeds

UCL, London